文献速递类风湿关节炎

类风湿关节炎稳定缓解患者的治疗减量与停药(RETRO):一项多中心、随机、对照、开放标签、3期试验

Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial.
PubMed 文献 · Lancet Rheumatol · 2021-10-01

RETRO研究在14家德国医院或风湿科诊所连续纳入303例稳定缓解的类风湿关节炎患者,随机分为继续100%剂量、减至50%剂量、50%剂量6个月后停药三组。12个月维持缓解比例继续组81.2%、减量组58.6%、停药组43.3%(趋势检验p=0.0005);减量组和停药组复发风险分别为继续组的3.02倍和4.34倍,多数复发者恢复100%剂量后重获缓解。

要点

  • 稳定缓解类风湿关节炎患者减量或停用DMARDs后12个月维持缓解比例低于继续100%剂量组。
  • 减量组和停药组复发风险显著高于继续组,作者认为此类策略需密切监测疾病活动。
  • 多数复发患者重新使用100%剂量DMARDs后重获缓解。

核心结论

  • 稳定缓解的类风湿关节炎患者减少抗风湿药物是可行的,约半数患者可维持缓解。
  • 减量或停药组复发率显著高于继续100%剂量组,此类方法需要密切监测疾病活动。
  • 本研究中多数复发患者重新使用抗风湿治疗后重获缓解,结果可能有助于避免大量患者过度治疗。

研究设计与样本

  • RETRO为研究者发起的多中心、前瞻性、随机、对照、开放标签、平行组3期试验。
  • 纳入年龄至少18岁、随机化前类风湿关节炎病程至少12个月、处于持续DAS28-ESR缓解(评分<2.6单位)的患者。
  • 从14家德国医院或风湿科诊所连续招募,按1:1:1随机分配至继续100%剂量DMARD组、减至50%剂量DMARD组、50%剂量DMARD 6个月后停药组,随机化未分层且不考虑基线治疗。
  • 患者每3个月评估一次,筛查疾病活动和复发,主要终点为12个月时无复发的持续DAS28-ESR缓解比例。
  • 主要结局和安全性在改良意向治疗人群(含基线数据非缺失的参与者)中分析;试验注册号NCT02779114。

主要发现

  • 2010年5月26日至2018年5月29日共入组303例患者,继续组100例、减量组102例、停药组101例;282例(93%)纳入分析(继续组93/100例[93%]、减量组93/102例[91%]、停药组96/101例[95%])。
  • 12个月维持缓解比例:继续组81.2%(95%CI 73.3-90.0)、减量组58.6%(95%CI 49.2-70.0)、停药组43.3%(95%CI 34.6-55.5),趋势log-rank检验p=0.0005。
  • 与继续组相比,减量组复发HR为3.02(95%CI 1.69-5.40;p=0.0003),停药组复发HR为4.34(95%CI 2.48-7.60;p<0.0001)。
  • 严重不良事件:继续组10/93例(11%)、减量组7/93例(8%)、停药组13/96例(14%),均认为与干预无关;最常见严重不良事件为损伤或操作并发症(n=9)。

关键数值与推荐

  • 持续缓解定义为DAS28-ESR评分<2.6单位。
  • 继续组为100%剂量DMARD,减量组为50%剂量DMARD,停药组为50%剂量DMARD 6个月后停药。
  • 12个月无复发持续缓解比例继续组81.2%、减量组58.6%、停药组43.3%(趋势检验p=0.0005)。
  • 减量组复发HR 3.02(95%CI 1.69-5.40;p=0.0003),停药组复发HR 4.34(95%CI 2.48-7.60;p<0.0001),均以继续组为参照。

临床怎么用

  • 作者认为稳定缓解患者减少抗风湿药物可行,约半数可维持缓解。
  • 作者指出减量或停药组复发率显著高于继续100%剂量组,此类方法需要密切监测疾病活动。
  • 作者报告多数复发患者重新使用抗风湿治疗后重获缓解,结果可能有助于避免大量患者过度治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Owing to increasing remission rates, the management of patients with rheumatoid arthritis in sustained remission is of growing interest. The Rheumatoid Arthritis in Ongoing Remission (RETRO) study investigated tapering and withdrawal of disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis in stable remission to test whether remission could be retained without the need to take DMARD therapy despite an absence of symptoms. METHODS: RETRO was an investigator-initiated, multicentre, prospective, randomised, controlled, open-label, parallel-group phase 3 trial in patients aged at least 18 years with rheumatoid arthritis for at least 12 months before randomisation who were in sustained Disease Activity Score using 28 joints with erythrocyte sedimentation rate (ESR) remission (score <2·6 units). Eligible patients were recruited consecutively from 14 German hospitals or rheumatology practices and randomly assigned (1:1:1) without stratification and regardless of baseline treatment, using a sequence that was computer-generated by the study statistician, to continue 100% dose DMARD (continue group), taper to 50% dose DMARD (taper group), or 50% dose DMARD for 6 months before stopping DMARDs (stop group). Neither patients nor investigators were masked to the treatment assignment. Patients were assessed every 3 months and screened for disease activity and relapse. The primary endpoint was the proportion of patients in sustained DAS28-ESR remission without relapse at 12 months, analysed using a log-rank test of trend and Cox regression. Analysis by a trained statistician of the primary outcome and safety was done in a modified intention-to-treat population that included participants with non-missing baseline data. This study is completed and closed to new participants and is registered with ClinicalTrials.gov (NCT02779114). FINDINGS: Between May 26, 2010, and May 29, 2018, 303 patients were enrolled and allocated to continue (n=100), taper (n=102), or stop DMARDs (n=101). 282 (93%) of 303 patients were analysed (93 [93%] of 100 for continue, 93 [91%] of 102 for taper, and 96 [95%] of 101 for stop). Remission was maintained at 12 months by 81·2% (95% CI 73·3-90·0) in the continue group, 58·6% (49·2-70·0) in the taper group, and 43·3% (34·6-55·5) in the stop group (p=0·0005 with log-rank test for trend). Hazard ratios for relapse were 3·02 (1·69-5·40; p=0.0003) for the taper group and 4·34 (2·48-7·60; p<0.0001)) for the stop group, in comparison with the continue group. The majority of patients who relapsed regained remission after reintroduction of 100% dose DMARDs. Serious adverse events occurred in ten of 93 (11%) patients in the continue group, seven of 93 (8%) patients in taper group, and 13 of 96 (14%) patients in the stop group. None were considered to be related to the intervention. The most frequent type of serious adverse event was injuries or procedural complications (n=9). INTERPRETATION: Reducing antirheumatic drugs in patients with rheumatoid arthritis in stable remission is feasible, with maintenance of remission occurring in about half of the patients. Because relapse rates were significantly higher in patients who tapered or stopped antirheumatic drugs than in patients who continued with a 100% dose, such approaches will require tight monitoring of disease activity. However, remission was regained after reintroduction of antirheumatic treatments in most of those who relapsed in this study. These results might help to prevent overtreatment in a substantial number of patients with rheumatoid arthritis. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Tascilar K, Hagen M, Kleyer A, et al. Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Rheumatol. 2021. PMID: 38297524. doi:10.1016/S2665-9913(21)00220-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。